Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye

MUMBAI, January 4, 2017 /PRNewswire/ --





- Seciera(TM) Meets Primary and Key Secondary Endpoints in Pivotal Trial

- Shows Efficacy at 12 Weeks of Treatment

- Sun Pharma is Developing Seciera(TM) for Global Markets

Sun Pharma announced successful Phase 3 confirmatory clinical trial results for Seciera(TM) (cyclosporine A, 0.09% ophthalmic solution), for the treatment of dry eye disease. Seciera(TM) is a patented, novel, proprietary nanomicellar formulation of cyclosporine A 0.09%. It is a clear, preservative-free, aqueous solution. Seciera(TM) is being developed by Ocular Technologies, a company recently acquired by Sun Pharma. Following this acquisition, Sun Pharma owns exclusive, worldwide rights to Seciera(TM) and is developing it to commercialize for global markets including US, Europe, and Japan, as well as several emerging markets.

(Logo: http://photos.prnewswire.com/prnh/20160711/813488 )



In this 12 week, multicenter, randomized, double-masked, vehicle controlled Phase 3 confirmatory study, 744 dry eye patients were treated either with Seciera(TM), or its vehicle.  After 12 weeks of treatment, as compared to vehicle, Seciera(TM) showed statistically significant improvement in the primary end point, Schirmer's score (a measurement of tear production) (p

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234